Phase 1 Study of TISA-818-Inj-5mg/mL in Idiopathic Pulmonary Fibrosis: Safety, Tolerability, and Pharmacokinetics in Healthy Adults

The primary objective of this study is to evaluate the **safety**, **tolerability**, and **pharmacokinetics** of TISA-818-Inj-5mg/mL following subcutaneous injection in healthy adult subjects. This is a phase 1, randomised, double-blind, placebo-controlled study involving both single ascending dose and multiple ascending dose regimens. The clinical relevance of this study lies in its potential to inform future therapeutic strategies for **idiopathic pulmonary fibrosis**, a progressive and debilitating lung disease. No secondary objectives are provided for this study.

The clinical trial involves participants diagnosed with **idiopathic pulmonary fibrosis**. The study population includes both male and female subjects, with an age range categorized as adults. The trial does not involve a vulnerable population. The sponsor has not provided information regarding the total number of participants. Participants were selected based on criteria not disclosed by the sponsor, and no specific lifestyle considerations such as diet, physical activity, or habits have been mentioned. Key inclusion or exclusion criteria have not been specified in the available data.

The clinical trial is designed as a **randomized**, **double-blind**, **placebo-controlled** study to assess the safety, tolerability, and pharmacokinetics of TISA-818-Inj-5mg/mL in healthy adult subjects. The trial will be conducted in two parts: a single ascending dose and a multiple ascending dose phase. The study targets **idiopathic pulmonary fibrosis**, a rare disease, and aims to gather data on the investigational product's effects when administered via subcutaneous injection. The trial is scheduled to commence on January 2, 2024, with an estimated completion date of September 30, 2024, indicating a total duration of approximately nine months.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to determine eligibility based on predefined criteria. Following successful screening, subjects will be randomized to receive either the investigational product or a placebo. The sequence of study visits will include regular follow-up assessments to monitor safety and collect pharmacokinetic data. These visits are crucial for evaluating the investigational product's effects over time and ensuring participant safety. The end-of-study visit will conclude the trial, during which final assessments will be conducted to gather comprehensive data on the investigational product's safety profile.

The expected length of participant involvement will vary depending on the dosing schedule assigned, but it will generally span the entire trial duration. Conditions that may lead to early termination from the study include adverse events, non-compliance with study procedures, or withdrawal of consent by the participant. The trial's design and procedures are structured to ensure rigorous data collection while maintaining participant safety and adherence to ethical standards.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its **pharmaceutical form**, dosage, route, and frequency of administration. Additionally, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, that may be used in the study. Furthermore, the documentation lacks details on drug administration, dosing schedules, and participant compliance monitoring. As such, no further description of the treatments can be provided based on the available data.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on January 2, 2024, with an estimated completion date of September 30, 2024. Efficacy will be evaluated using specific parameters or endpoints, although these are not detailed in the provided data. The methods and schedule for measuring, collecting, and analyzing these efficacy parameters are not specified. The trial will adhere to the rigorous standards expected in Phase 3 studies, ensuring that the data collected will be robust and reliable for assessing the efficacy of the intervention under investigation.